Prediction of patients with a tumor proportion score > 50% who do not respond to first-line monotherapy with pembrolizumab | BMC Cancer | Full Text

Prediction of patients with a tumor proportion score > 50% who do not respond to first-line monotherapy with pembrolizumab | BMC Cancer | Full Text

Prediction of patients with a tumor proportion score > 50% who do not respond to first-line monotherapy with pembrolizumab

Pembrolizumab is effective as first-line therapy against advanced non-small cell lung cancer (NSCLC) in patients with programmed death ligand-1 (PD-L1) expression levels ≥50% [1]. However, it is not effective ...

Authors:Mitsunori Morita, Motohiro Tamiya, Daichi Fujimoto, Akihiro Tamiya, Hidekazu Suzuki, Katsuya Hirano, Yasushi Fukuda, Toshihide Yokoyama, Ryota Kominami, Masaki Kanazu, Junji Uchida, Satoshi Hara, Shuji Yamashita and Hiromi Tomioka

Citation:BMC Cancer 2020 20:93

Content type:Research article

Published on: 3 February 2020

• ViewFull Text
 
• ViewPDF